Université Joseph Fourier

Centre National De La Recherche Scientifique

Commissariat a L'energie Atomique

University of Medicine and Dentistry of New Jersey

Université De Poitiers

Université Joseph Fourier - Grenoble 1

Universite Pierre Et Marie Curie—paris 6 (upmc)

University Joseph Fourier (grenoble 1)

Universite Joseph Fourier De Grenoble

Commissariat &#xc0; L'&#xc9;nergie Atomique Et Aux &#xc9;nergies Alternatives

Jean-Luc Decout

Marc Fontecave

Frederic Becq

Cécile Dueymes

Jerome Desire

Isabelle Baussanne

Jean-Marc Paris

Philippe Peltie

Pierre Lehn

Marc Cuzin

Caroline Norez

Isabelle Callebaut

Clement Boinot

Eric Peyrin

Corrine Ravelet

Christel Routaboul

Brice Hoffman

Julien Alliot

Virendra N Pandey

Benjamin Boucherle

Emmanuel Riguet

Jean-Paul Mornon

Romain Haudecoeur

Antoine Fortune

Beatrice Gerland

Isabelle Baussane

Jérôme Desire

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula (I) for the treatment of cystic fibrosis. The invention also relates to a process for manufacturing compounds of Formula (I). 

Compounds for treating cystic fibrosis

This invention concerns compounds with the formula: in which:

Synthesis of novel neamine derivatives and use thereof as antibacterial agents

Process for preparing a compound of the formula (I) R1-S(O)&#x2014;S(O)R2 in which R1 represents a molecular hydrocarbon radical which can be substituted and/or interrupted by one or more atoms and/or by one or more groups containing one or more atoms, said atoms being selected from N, O, P, S, Si and X, where X represents a halogen; R2, independently of R1, represents a carbon-containing group or a molecular hydrocarbon radical which can be substituted and/or interrupted by one or more atoms and/or by one or more groups containing one or more atoms, said atoms being selected from N, O, P, S, Si and X, where X represents a halogen, and x and y are selected from 0 and 1 in such a way that the sum of x and y is not more than 1, characterized in that a compound of formula (II) R1-S(O)&#x2014;R3-Si(R4)(R5)(R6) in which R3 represents a hydrocarbon chain of two carbon atoms, which is optionally unsaturated and/or substituted, and R4, R5 and R6, which are identical or different, each represent, independently of one another, a hydrocarbon group, is reacted with a compound of formula (VII) R2-S(O)&#x2014;X in which X represents a halogen, intermediate compounds, and compounds prepared.

Process for preparing disulfides and thiosulphinates and compounds prepared

The invention relates to the use of compounds as new chiral selectors for separating the optical or enantiomeric isomers of a compound, wherein the chiral selector comprises at least one compound of formula (I): and at least one metal ion, for example Cu, Ni, Zn, Cdor Co. 

Chiral selectors for separating enantiomers of a compound

The invention concerns pharmaceutical formulas designed for the treatment of diseases related to CFTR channel dysfunction, such as cystic fibrosis, asthma or diarrhoea. These formulas contain a molecule, coming in the form of a zwitterion at physiological pH, with the general formula: where X&#x2550;N or P; and A representative example is: 

CFTR channel modulators

The present invention relates to methods and compositions pertaining to conjugates composed of a peptide nucleic acid (PNA) moiety and a neamine derivative moiety. Methods for using such conjugates for modulating the activity of a target nucleic acid molecule and for preventing or treating a disease associated with an aberrant nucleic acid molecule are also provided.

PNA-neamine conjugates and methods for producing and using the same

The invention concerns a method for analyzing biological targets of DNA or RNA type, which comprises the following steps:

Method and support for biological analysis using oligonucleotides comprising a marker capable of enzymatic activation

This invention relates to an analytical support containing a plurality of oligonucleotides fixed on this support, where each of the nucleotides is marked by a fluorescent compound that presents a variation of fluorescence on the hybridization of each marked oligonucleotide with at complementary oligonucleotide. This support makes it possible to carry out an analysis of biological targets by measuring the variation of fluorescence in order to determine the hybridization of the targets with the oligonucleotides of the support.

Analysis of biological targets using a biochip comprising a fluorescent marker

Growing community of inventors

Vaulnaveys le Haut, France

Jean-Luc Decout